1. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982; 100:1132–40.
Article
2. Cahill MT, Fekrat S. Arteriovenous sheathotomy for branch retinal vein occlusion. Ophthalmol Clin North Am. 2002; 15:417–23.
Article
3. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia Blue Mountains Eye Study. Arch Ophthalmol. 1996; 114:1243–7.
4. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984; 98:271–82.
5. Greer DV, Constable IJ, Cooper RL. Macular edema and retinal branch vein occlusion. Aust J Ophthalmol. 1980; 8:207–9.
6. Kohner EM, Pettit JE, Hamilton AM. Streptokinase in central retinal vein occlusion:a controlled clinical trial. Br Med J. 1976; 6:550–3.
7. Hattenbach LO, Steinkamp G, Scharrer I, Ohrloff C. Fibrinolytic therapy with low dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica. 1998; 212:394–8.
8. Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers. 1999; 30:427–34.
Article
9. Glancerbernard A, kuhn D, Vine AK, et al. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000; 84:609–13.
10. Elman MJ, Raden RZ, Carrigan A. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc. 2001; 99:219–21.
Article
11. Tomoaki M, Hitoshi T, Mihori K, et al. Intravitreal tissue plasminogen activator to treat macular edema associated With branch retinal vein occlusion. Am J Ophthalmol. 2006; 142:318–20.
12. Kim HC, Kwon SI, Kim HK. The effect of intravitreal injection of tPA and C3 F8 in submacular hemorrhage. J Korean Ophthalmol Soc. 2000; 40:400–9.
13. Tomoaki M, Akitaka T, Masafumi O, et al. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol. 2007; 143:171–3.
14. Nicola G, Baha N, Randa S, et al. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina. 2003; 23:780–4.
Article
15. Mahmoud TH, Peng YW, Proia A, et al. Intravitreal tissue plasminogen activator penetrates the retinal vessels in a porcine model of vascular occlusion. Invest Ophthalmol Vis Sci. 2002; 43:353.
16. Gandorfer A. Pharmacologic vitreolysis. Dev Ophthalmol. 2007; 39:149–56.
Article
17. Hermel M, Schrage NF. Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study. Graefes Arch Clin Exp Ophthalmol. 2007; 245:399–406.
Article
18. Li X, Shi X, Fan J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol. 2002; 240:56–62.
Article
19. Ohji M, Saito Y, Hayashi A, et al. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998; 116:1326–32.
Article
20. Gopalakrishan M, Giridhar A, Bhat S, et al. Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection. Retina. 2007; 27:329–34.